BTX DD courtesy of KELT BioTime Shorters Get It Wrong,

New Post Public Reply Private Reply Replies (0) Message Board
biomanbaba

BTX DD courtesy of KELT

BioTime Shorters Get It Wrong, Again
By the way, do you remember a few months ago when the short attackers were mounting a full assault of Star Scientific? Some of you, I know, used the opportunity to add to your portfolios. Some of those short attackers accused me of being part of some kind of conspiracy to promote Star Scientific, though I own none of the company’s stock.
The same thing is happening with regard to  BioTime (AMEX: BTX). It’s not the first time, but the attacks are particularly blatant now. I’m being named personally, and a website has been established on an Asian provider known to host malware.
I’m not going to link to any of this stuff, which is appearing on a relatively large investment-oriented website. I don’t want to give it traffic. I will say, however, that the website’s owners seem to have gone seriously off-track. I’ve heard that they are trying to sell the site, and it makes no sense that they would allow the sort of wildly inaccurate claims that are being made. An SEC probe right now could be very detrimental to any possible sale.
It’s odd, in fact, just how badly done these short attacks really are. It seems to me as if they’re not even trying to be accurate, but simply tossing out lies to fool the easily misled.
For example, I’ve heard that the attackers claim that my readers are 70% down on  Geron (NASDAQ: GERN). In fact, you may recall that I gave the sell recommendation in 2010 for an 86% gain. The attackers also say that BioTime is down 7%. In fact, it’s up around 400%. I don’t even really check the price regularly, because the company has only begun to perform.
Similarly, the writer or writers say that BioTime CEO Dr. Michael West is somehow responsible for the failures of Geron and Advanced Cell Technology, which would be remarkable, as he never ran either of those companies. He helped found both, but acted only as a scientist, and actually left them, with most of his important patents and discoveries, when managements were sidetracked.
BioTime is the first company that West has helmed. Let’s look at just a few of the people who have given him their confidence, so you can compare their credibility to the short attackers.
Dr. Arnold Caplan, the father of adult stem cell medicine, founded Osiris Therapeutics (OSIR) but jumped ship to join BioTime’s On coCyte. This faith was just shown to be justified by BioTime’s announcement that it has developed the first true cartilage stem cells. Caplan is professor of oncology at Case Western Reserve University.
Dr. Andrew von Eschenbach was head of the FDA, as well as president of the American Cancer Society. His knowledge and connections make him one of the most important people in the pharmaceutical industry today, especially in the arena of oncology. He’s chosen to join BioTime, in large part because of the company’s breakthrough cancer diagnostic tools, which should be approved in Europe next year.
Dr. David Warshawsky’s decision to bring the world’s most-important and profitable bioinformatic database, XenneX, into the BioTime fold is a critical example of the scientific community’s confidence in BioTime. It also reflects the association of Israel’s extremely prestigious Weizmann Institute of Science, which developed the program.
The point is that these are the sorts of people who have placed their trust in Dr. West. I could go on, and will in later issues. Today, however, I’d like to show you a picture of my living cells growing in vitro at BioTime.
In coming weeks, I’ll show you other pictures that demonstrate BioTime’s unique technological ability to transform those cells into induced pluripotent stem cells. This process, blocking Sp100 gene expression, will be far superior to the Yamanaka virus vector method, which is slow, uncertain and destructive to cells. Since the short attackers are interested only in driving down the price of the stock so they can profit from their shorts, it won’t matter to them.
Further down the road, these cells will be precisely programmed to become beating heart muscle cells — with my DNA. West could put them back into my body and I would have no immune reaction. If other studies are an indication, they would provide system benefits to my health. West could as easily turn them into endothelial precursors, which would have the power to completely rejuvenate my cardiovascular system.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 163

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 89

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 129

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 120

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 25

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 25

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 144

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 74

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 84

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading

Top 5 Most Recently Viewed Articles

Joseph Margolis Shows Strong Faith in Extra Space Storage

Updated Category News Views 133

Joseph Margolis Shows Strong Faith in Extra Space Storage Recently, a significant insider purchase was conducted by Joseph Margolis, who holds the position of Chief Executive Officer at Extra Space Storage (EXR). According to the latest SEC filing, Margolis acquired 27,741 shares of the company, amounting to a considerable investment of $4,232,166. The market had a...

Continue Reading
Investigation Into Arcadium Lithium Sale Sparks Concerns

Updated Category News Views 192

Investigation Launched into Arcadium Lithium Shareholder Rights The former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., is leading an inquiry regarding an important corporate transaction involving Arcadium Lithium plc (NYSE: ALTM). This investigation, undertaken by the law firm Kahn Swick & Foti, LLC, seeks to assess whether the terms of the proposed sale to...

Continue Reading
Actian Introduces Advanced Federated Data Catalog for Businesses

Updated Category News Views 148

Actian Launches Innovative Federated Data Catalog Actian, the data and analytics division of HCLSoftware, is setting new standards in data management with the introduction of the Actian Zeenea Federated Data Catalog. This advanced platform simplifies data discovery, empowering users across enterprises to harness valuable data resources effectively. With the acquisition of...

Continue Reading
Oil-Dri Corporation Reports Impressive Second Quarter Growth

Updated Category News Views 123

Oil-Dri Corporation Achieves Significant Growth Oil-Dri Corporation of America (NYSE: ODC), a reputable name in the production and marketing of sorbent mineral products, has shared its impressive financial performance for the second quarter of fiscal 2025, marking substantial growth for the company. Financial Highlights of the Second Quarter During this reporting period,...

Continue Reading
Power Metallic: Drill Assays Fuel Growth Optimism at Lion

Updated Category News Views 34

Striking Copper: Panning Out or Fools' Gold? Well, here's a dose of copper digging straight from the heart of the Lion Zone with Power Metallic Mines (TSXV: PNPN, OTCBB: PNPNF) at the helm. Now, if copper's your game, the latest assay results might just tickle your fancy. We're talking hefty 13.30 meters at 3.98% CuEqRec in hole 26-115 and, get this, a juicy 5.26 meters...

Continue Reading